Temporalis muscle thickness as an indicator of sarcopenia predicts progression-free survival in head and neck squamous cell carcinoma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • Subject Terms:
    • Abstract:
      Temporalis muscle thickness (TMT) on brain magnetic resonance imaging (MRI) is correlated with sarcopenia and can be a predictive marker for survival in patients with brain tumors, but the association of TMT on head and neck computed tomography (CT) with survival in head and neck squamous cell carcinoma (HNSCC) remains unclear. We investigated whether TMT on CT could predict progression-free survival (PFS) in patients with HNSCC. A total of 106 patients with newly diagnosed HNSCC were included in this retrospective study. The patients underwent baseline head and neck CT and/or MRI between July, 2008 and August, 2018. The correlation between TMT on CT and MRI was tested using intraclass correlation coefficient (ICC). The cut-off value of TMT on CT for determining tumor progression was identified using receiver-operating characteristic curve analysis. Uni- and consecutive multi-variable Cox regression models were used to verify the association between TMT and PFS. TMT on CT and MRI showed excellent correlation (ICC, 0.894). After a mean follow-up of 37 months, 49 out of 106 patients showed locoregional recurrence and/or distant metastasis. The cut-off TMT of 6.47 mm showed good performance in predicting tumor progression (area under the curve, 0.779). The Cox regression model showed that TMT ≤ 6.24 mm (median value in study population) was a significant contributing factor for predicting shorter PFS (hazard ratio 0.399; 95% confidence interval 0.209-0.763; P = .005). TMT may be used as a surrogate parameter for pre-treatment sarcopenia and could help predict PFS in patients with HNSCC.
      (© 2021. The Author(s).)
    • References:
      ORL J Otorhinolaryngol Relat Spec. 2018;80(1):1-9. (PMID: 29393251)
      Br J Cancer. 2012 Sep 4;107(6):931-6. (PMID: 22871883)
      J Surg Oncol. 2015 May;111(6):771-5. (PMID: 25556324)
      PLoS One. 2012;7(4):e34444. (PMID: 22509305)
      PLoS One. 2018 Nov 29;13(11):e0207849. (PMID: 30496307)
      JAMA Oncol. 2016 Jun 1;2(6):782-9. (PMID: 26891703)
      Oral Oncol. 2016 Nov;62:28-33. (PMID: 27865369)
      J Neurooncol. 2018 Oct;140(1):173-178. (PMID: 30008154)
      Ann Surg Oncol. 2015 Aug;22(8):2663-8. (PMID: 25564158)
      CA Cancer J Clin. 2017 Mar;67(2):93-99. (PMID: 28094848)
      J Cancer Res Clin Oncol. 2021 Mar;147(3):901-909. (PMID: 32929611)
      Oral Oncol. 2017 Aug;71:26-33. (PMID: 28688687)
      J Clin Oncol. 2013 Apr 20;31(12):1539-47. (PMID: 23530101)
      Eur Radiol. 2017 Aug;27(8):3167-3173. (PMID: 28050694)
      JAMA Otolaryngol Head Neck Surg. 2019 Jul 1;145(7):647-654. (PMID: 31169874)
      AJR Am J Roentgenol. 2011 Jul;197(1):W134-40. (PMID: 21700974)
      J Appl Physiol (1985). 2004 Dec;97(6):2333-8. (PMID: 15310748)
      Head Neck. 2019 Jun;41(6):1745-1755. (PMID: 30663159)
      Korean J Radiol. 2015 Nov-Dec;16(6):1294-302. (PMID: 26576119)
      Curr Opin Support Palliat Care. 2009 Dec;3(4):269-75. (PMID: 19667996)
      Dis Esophagus. 2016 Aug;29(6):627-33. (PMID: 26123787)
      Lancet Oncol. 2008 Jul;9(7):629-35. (PMID: 18539529)
      J Urol. 2014 Jun;191(6):1714-20. (PMID: 24423437)
      Br J Surg. 2013 Oct;100(11):1523-30. (PMID: 24037576)
      JAMA Otolaryngol Head Neck Surg. 2017 Dec 1;143(12):1159-1165. (PMID: 28448668)
    • Accession Number:
      0 (Biomarkers)
    • Publication Date:
      Date Created: 20211006 Date Completed: 20211229 Latest Revision: 20211229
    • Publication Date:
      20221213
    • Accession Number:
      PMC8492642
    • Accession Number:
      10.1038/s41598-021-99201-3
    • Accession Number:
      34611230